Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
Treatme...
...General Recommendations for G1–G...
...dation 1.1Selection of initial treatm...
...1.2All treatment decisions should be guide...
...ecommendation 1.3Patients should be assessed...
...emic Therapy for Metastatic G1–G2 Gastrointe...
...ine Systemic Therapy for G1–G2 GI-NETs...
...commendation 2.1SSAs (octreotide or lanreotide) ar...
...2.2In the less common circumstance of patien...
...- or Later-line Systemic Therapy for...
...2.3Peptide receptor radionuclide therapy (PRRT)...
...tion 2.4Everolimus is recommended for patie...
...ystemic Therapy for Metastatic G1–G2 P...
...rst-line Systemic Therapy for G1–G2 p...
...ommendation 3.1SSAs (octreotide or lanreotide) are...
...on 3.2Chemotherapy (e.g., capecitabine and t...
Recommendation 3.3Chemotherapy (e.g., CAPTEM), e...
...ond- or Later-line Systemic Therap...
...ommendation 3.4PRRT for SSTR-positive tumors, ch...
...ic Therapy for G3 GEP-NETs...
...4.1The range of systemic options outlined...
...HO Classification and Grading Crite...
...gure 1. Systemic Therapy for Tumor Control in W...
...that cancer clinical trials are vital to infor...